Formularyjournal.modernmedicine.com

The wait continues. An FDA ruling on a Duchenne muscular dystrophy drug from Sarepta Therapeutics—which could be the first ever approved for the disease—has been imminent for a while now, yet Labor Day is fast approaching and still the saga drags on...

WASHINGTON » At age 7, Josh Hardy became the poster child for a movement to help desperately ill or dying patients access experimental therapies which, they hope, will save their lives. People around the world rallied 21/2 years ago when a small biotech...

February 15, 2017 By Deena Beasley (Reuters) – U.S. President Donald Trump’s vow to roll back government regulations at least 75 percent is causing anxiety for some pharmaceutical executives that a less robust Food and Drug Administration would make...

FDA approves drug for terminal muscular dystrophy – but manufacturer hikes the price from $1,000 to $89,000 a year A pharmaceutical company has been forced to ‘pause’ the launch of a crucial muscular dystrophy drug amid outrage over its $88,000 price...

The launch of Marathon Pharmaceuticals’ steroid drug, Emflaza (deflazacort), has been delayed following outrage over the drug’s price. On February 9, 2017, the FDA announced the approval of the new drug to treat a rare genetic disorder, Duchenne muscular...